跳至主要内容
临床试验/NCT03518658
NCT03518658已完成不适用

BlueSync Field Evaluation

Medtronic Cardiac Rhythm and Heart Failure20 个研究点 分布在 4 个国家目标入组 257 人开始时间: 2018年4月2日最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
发起方
入组人数
257
试验地点
20
主要终点
Chronic CareLink Transmission Success

研究概览

简要总结

The purpose of this field evaluation is to collect and evaluate information related to CareLink transmission compliance as well as patient perceived benefit of BlueSync™ and the health care provider perception of the value of BlueSync™ and satisfaction with BlueSync™.

详细描述

The primary goal is to learn how many CareLink quarterly scheduled transmissions are completed within a prescribed time period to assess CareLink scheduled transmission compliance. The evaluation will also assess adoption to remote monitoring, patient perceived benefit of BlueSync™ (how patients interact with the smart device application) and health care provider perception of the value of BlueSync™ and satisfaction with BlueSync™ (benefits experienced by clinicians that use BlueSync™).

This clinical trial information was submitted voluntarily under the applicable law and, therefore, certain submission deadlines may not apply. (That is, clinical trial information for this applicable clinical trial was submitted under section 402(j)(4)(A) of the Public Health Service Act and 42 CRF 11.60 and is not subject to the deadlines established by sections 402(j)(2) and (3) of the Public Health Service Act or 42 CRF 11.24 and 11.44).

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Prospective

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者
否

入选标准

  • •Patient will be/has been implanted with an Azure™ or Percepta™, Serena™, Solara™ CRT-P device compatible with BlueSync™ (both new and replacement devices are allowed)
  • •Patient must own a smart device (Smartphone or tablet) that meets system requirements and be willing to use during evaluation period
  • •Patient must be able to complete the required 12-month follow-up after enrollment
  • •Patients must be of legal age according to local law

排除标准

  • •Patient unwilling to complete required surveys during 12-month evaluation period

结局指标

主要结局

Chronic CareLink Transmission Success

时间窗: Scheduled transmissions between 1 and 12 months after enrollment/CareLink activation

To assess CareLink transmission compliance (adherence to scheduled transmission), the primary objective is to compare the percentages of the CareLink quarterly scheduled transmissions that are completed within the prescribed window during the 12-month follow-up after the baseline visit in the CareLink Database between the evaluation patients who use the MyCareLink Heart™ (MCL) app and patients with low power devices and CareLink monitors 2490 (excluding wireless model 2490C). For both patient groups, all scheduled transmissions between 1 and 12 months after enrollment/CareLink activation were included. The results reflect the total percentage of completed transmissions pooled across subjects taking into account that there were several transmissions per subject. A correlated data method was required for the analysis. A 95% confidence interval based on generalized estimating equations for binomial distribution was calculated for the percentage of completed scheduled transmissions.

次要结局

  • Acute CareLink Transmission Success(Scheduled transmissions in the first month after enrollment)

研究者

发起方
Medtronic Cardiac Rhythm and Heart Failure
申办方类型
Industry
责任方
Sponsor

研究点 (20)

Loading locations...

相似试验